ArticleResearch square2026
Mapping the resistance landscape: A large-scale study of polymyxin-resistant pathogens circulating in low-and middle-income countries.
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
Abstract
The increasing prevalence of antimicrobial resistance is a major public health challenge, particularly in low- and middle-income countries (LMICs). Polymyxins are last-resort antibiotics used for treating highly drug-resistant infections, however, the rise of polymyxin-resistant bacterial strains is further reducing treatment options in LMICs, where the burden is exacerbated by limited diagnostic capacity, poor antimicrobial stewardship, and limited surveillance infrastructure. There is a lack of comprehensive population-based surveillance of the emerging polymyxin resistance and a need to comprehend what genetic determinants are associated with this resistance. In this study, we collected 634 clinical isolates of polymyxin-resistant bacteria from 28 LMICs, then used whole genome sequencing, phylogenetic and bioinformatic analyses to identify species, sequence types and antibiotic resistance gene profiles. We found 12 bacterial species and focussed downstream analyses on 4 high priority pathogens:
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.